Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2019
Filed with the SEC on Feb 14, 2020 and accepted by EDGAR at Feb 14, 2020, 17:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2019-10-01 to 2019-12-31 | $7.6k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-07-01 to 2019-12-31 | $18.2k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2019-10-01 to 2019-12-31 | $37 | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-07-01 to 2019-12-31 | $65.4k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-07-01 to 2019-12-31 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-10-01 to 2019-12-31 | $446.1k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-07-01 to 2019-12-31 | $1.1m | us-gaap:InterestExpense |
| Income tax | 3 months2019-10-01 to 2019-12-31 | $143 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-07-01 to 2019-12-31 | −$108.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$1.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-07-01 to 2019-12-31 | −$3.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$1.25 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-07-01 to 2019-12-31 | −$2.64 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-07-01 to 2019-12-31 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-12-31 | $12.0k | us-gaap:Cash |
| Current assets | At period end2019-12-31 | $20.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $65.4k | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $5.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $5.7m | us-gaap:Liabilities |
| Long-term debt | At period end2019-12-31 | $2.9m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-12-31 | −$5.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-002576. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.